Johannes Rolin, Rønnaug Astri Ødegård, Viktoria Vedeler Amundsen, Unni Mette Stamnes Köpp, Ane Kokkvoll, Pétur Benedikt Júlíusson, Jøran Hjelmesæth
{"title":"补充药物治疗减轻青少年严重肥胖的体重。","authors":"Johannes Rolin, Rønnaug Astri Ødegård, Viktoria Vedeler Amundsen, Unni Mette Stamnes Köpp, Ane Kokkvoll, Pétur Benedikt Júlíusson, Jøran Hjelmesæth","doi":"10.4045/tidsskr.22.0540","DOIUrl":null,"url":null,"abstract":"In 2021, the Norwegian Medicines Agency approved the use of daily injection of liraglutide 3.0 mg (Saxenda) as a supplement to lifestyle treatment for weight control in children ≥ 12 years of age with obesity (isoBMI ≥ 30). We share the treatment experiences of six multidisciplinary obesity clinics in the specialist health service.","PeriodicalId":520817,"journal":{"name":"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Supplementary drug treatment to reduce weight in adolescents with severe obesity.\",\"authors\":\"Johannes Rolin, Rønnaug Astri Ødegård, Viktoria Vedeler Amundsen, Unni Mette Stamnes Köpp, Ane Kokkvoll, Pétur Benedikt Júlíusson, Jøran Hjelmesæth\",\"doi\":\"10.4045/tidsskr.22.0540\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In 2021, the Norwegian Medicines Agency approved the use of daily injection of liraglutide 3.0 mg (Saxenda) as a supplement to lifestyle treatment for weight control in children ≥ 12 years of age with obesity (isoBMI ≥ 30). We share the treatment experiences of six multidisciplinary obesity clinics in the specialist health service.\",\"PeriodicalId\":520817,\"journal\":{\"name\":\"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4045/tidsskr.22.0540\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/10/11 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4045/tidsskr.22.0540","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/10/11 0:00:00","PubModel":"Print","JCR":"","JCRName":"","Score":null,"Total":0}
Supplementary drug treatment to reduce weight in adolescents with severe obesity.
In 2021, the Norwegian Medicines Agency approved the use of daily injection of liraglutide 3.0 mg (Saxenda) as a supplement to lifestyle treatment for weight control in children ≥ 12 years of age with obesity (isoBMI ≥ 30). We share the treatment experiences of six multidisciplinary obesity clinics in the specialist health service.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
